Human fibrin glue ensures hemostasis and effective bleeding control. Its primary function is promoting rapid clot formation at the application site. The glue significantly reduces the risk of excessive blood loss during surgical procedures by facilitating quick and reliable hemostasis. This is particularly crucial in diverse medical specialties where controlling bleeding is paramount. The ability of human fibrin glue to swiftly form clots enhances the overall safety of surgeries, minimizes bleeding-related complications, and contributes to better patient outcomes.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-human-fibrin-glue-market
Data Bridge Market Research analyses the Global Human Fibrin Glue Market is expected to reach USD 934.68 million by 2029 from USD 486.58 million in 2021, growing at a CAGR of 9.2% in the forecast period of 2022 to 2029. The global human fibrin glue market is driven by the increasing prevalence of surgical procedures worldwide, especially complex surgeries across diverse medical specialties. As surgical interventions become more commonplace, there is a growing demand for efficient hemostatic agents, with human fibrin glue emerging as a significant solution to address this need.
Key Findings of the Study
Growing awareness of advanced hemostatic solutions is expected to drive the market's growth rate
The growing awareness of advanced hemostatic solutions, including human fibrin glue, is a key driver in the global market. Healthcare professionals, particularly surgeons and medical practitioners, increasingly recognize these advanced solutions' benefits. Human fibrin glue offers faster and more reliable hemostasis, addressing a critical need in various surgical procedures. As awareness spreads about the advantages of these products, their adoption is rising globally. This heightened recognition among healthcare providers significantly influences market growth, reflecting a shift towards advanced and effective hemostatic solutions in medical practices worldwide.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022-2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Package Form (Liquid, Patch, Others), Application (Cardiac Surgery, Pulmonary Surgery, Burn Bleeding, Vascular Surgeries, Orthopedic Surgeries, Lacerations of liver and Spleen, Neurosurgery, Plastic Surgery, General Surgery, Wound Management, others), Distribution Channel (Direct Tender and Retail Sales), End User (Hospitals, Ambulatory Care Centers, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Services, Inc. (U.S.), Baxter (U.S.), CSL Limited (Australia), Shanghai RAAS (China), Corza Health (U.S.), Marquee Biosurgical (U.S.), Hualan Biological Engineering, Inc. (China)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global human fibrin glue market is segmented on the basis of package form, application, end user, and distribution channel.
- On the basis of package form, the global human fibrin glue market is segmented into liquid, patch, and others
- On the basis of application, the global human fibrin glue market is segmented into cardiac surgery, pulmonary surgery, burn bleeding, vascular surgeries, orthopedic surgeries, lacerations of liver and spleen, neurosurgery, plastic surgery, general surgery, wound management, and others
- On the basis of end user, the global human fibrin glue market is segmented into hospitals, ambulatory care centre, speciality clinics, and others
- On the basis of distribution channel, the global human fibrin glue market is segmented into direct tender and retail sales
Major Players
Data Bridge Market Research recognizes the following companies as the major global human fibrin glue market players in global human fibrin glue market are Johnson & Johnson Services, Inc. (U.S.), Baxter (U.S.), CSL Limited (Australia), Shanghai RAAS (China), Corza Health (U.S.), Marquee Biosurgical (U.S.), Hualan Biological Engineering, Inc. (China)
Market Developments
- In December 2019, Ethicon, a part of the Johnson & Johnson Family of Companies, launched a groundbreaking medical solution with the launch of VISTASEAL Fibrin Sealant (Human). This innovative product, containing a combination of fibrinogen and thrombin—essential clotting proteins found in human plasma—was specifically designed to assist surgeons in managing bleeding during surgical procedures. The introduction of VISTASEAL not only addressed a critical need in surgical practice but also significantly expanded Ethicon's product pipeline, reinforcing their commitment to advancing medical solutions within the Johnson & Johnson Family of Companies
- In March 2018, Baxter's strategic acquisition of hemostat and sealant products from Mallinckrodt holds significant implications for the global human fibrin glue market. Baxter achieved a milestone by completing the acquisition of two hemostat and sealant products from Mallinckrodt plc. The acquisition aligns with the increasing demand for advanced hemostatic agents, such as human fibrin glue, in surgical and medical procedures. By enhancing their hemostatic product pipeline, Baxter demonstrates a commitment to addressing the evolving needs of healthcare professionals and patients globally. This strategic expansion positions Baxter as a key player in the market, contributing to the growth and innovation in the field of hemostasis on a global scale
Regional Analysis
Geographically, the countries covered in the global human fibrin glue market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis
Asia-Pacific is the dominant region in the global human fibrin glue market during the forecast period 2022-2029
In the Asia Pacific, China dominates the market due to a combination of factors. Increasing awareness of hemostasis among the population and rising demand for human fibrin glue reflects a growing recognition of the importance of effective blood clotting in medical procedures. The surge in demand is also fueled by advancements in medical practices, an expanding healthcare infrastructure, and government initiatives supporting healthcare innovation.
North America is estimated to be the fastest growing region in global human fibrin glue market the forecast period 2022-2029
In the North America, the U.S. is expected to dominate the healthcare domain, driven by a combination of advanced technological capabilities and a significant burden of chronic diseases. With a forefront position in healthcare technology, the U.S. consistently invests in research and development, fostering innovation in diagnostics, treatment modalities, and medical processes. The prevalence of chronic diseases, such as cardiovascular conditions and diabetes, underscores the demand for ongoing and sophisticated medical interventions. Bolstered by a robust healthcare infrastructure, including top-tier medical institutions, the U.S. serves as a hub for medical excellence and research collaboration.
For more detailed information about the global human fibrin glue market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-human-fibrin-glue-market
